Department of Outcomes Research, Cleveland Clinic, Cleveland, OH 44195, USA.
Anesth Analg. 2012 Nov;115(5):1078-84. doi: 10.1213/ANE.0b013e3182662e01. Epub 2012 Sep 25.
Perioperative ketamine infusion reduces postoperative pain; perioperative lidocaine infusion reduces postoperative narcotic consumption, speeds recovery of intestinal function, improves postoperative fatigue, and shortens hospital stay. However, it is unknown whether perioperative IV lidocaine and/or ketamine enhances acute functional recovery. We therefore tested the primary hypothesis that perioperative IV lidocaine and/or ketamine in patients undergoing open abdominal hysterectomy improves rehabilitation as measured by a 6-minute walk distance (6-MWD) on the second postoperative morning.
Women having open hysterectomy were anesthetized with sevoflurane, followed by patient-controlled morphine. Patients were factorially randomized to one of the following groups: (1) lidocaine and placebo, (2) placebo and ketamine, (3) placebo and placebo, or (4) lidocaine and ketamine. Lidocaine was given as a bolus (1.5 mg/kg), followed by lidocaine infusion of 2 mg/kg/h for the first 2 hours, and then 1.2 mg/kg/h for 24 postoperative hours. Ketamine was given as a bolus (0.35 mg/kg), followed by ketamine infusion of 0.2 mg/kg/h for the first 2 hours, and then 0.12 mg/kg/h for 24 postoperative hours. The primary double-blind outcome was 6-MWD on the second postoperative morning; secondary outcomes included pain scores, opioid consumption, postoperative nausea and vomiting, and fatigue score.
The study was stopped after a planned interim analysis of 64 patients showed that lidocaine crossed the preplanned futility boundary, with mean ± SD of 202 ± 66 m versus 202 ± 73 m for lidocaine versus placebo, respectively, and mean difference (interim adjusted 97.5% confidence interval) of 0.93 m (-52, 54) (P = 0.96); the ketamine effect also crossed the futility boundary, with mean ± SD of 193 ± 77 m versus 210 ± 61 m for ketamine versus placebo, respectively, and mean difference (interim adjusted 97.5% confidence interval) of -11 m (-65, 44) (P = 0.54). No interaction between the 2 intervention effects was observed (P = 0.96). Neither intervention significantly influenced any of the secondary outcomes.
Our results do not support use of lidocaine or ketamine for improving 6-MWD on the second postoperative day after open hysterectomy.
围手术期氯胺酮输注可减轻术后疼痛;围手术期利多卡因输注可减少术后阿片类药物的消耗,加速肠道功能恢复,改善术后疲劳,缩短住院时间。然而,尚不清楚围手术期静脉内利多卡因和/或氯胺酮是否会增强急性功能恢复。因此,我们检验了主要假设,即接受开腹子宫切除术的患者围手术期静脉内利多卡因和/或氯胺酮可通过术后第二天的 6 分钟步行距离(6-MWD)改善康复。
接受七氟醚全身麻醉的女性随后接受患者自控吗啡麻醉。患者按因子随机分为以下组之一:(1)利多卡因和安慰剂,(2)安慰剂和氯胺酮,(3)安慰剂和安慰剂,或(4)利多卡因和氯胺酮。给予利多卡因(1.5mg/kg)推注,然后以 2mg/kg/h 的速度输注 2 小时,然后以 1.2mg/kg/h 的速度输注 24 小时。给予氯胺酮(0.35mg/kg)推注,然后以 0.2mg/kg/h 的速度输注 2 小时,然后以 0.12mg/kg/h 的速度输注 24 小时。主要的双盲结局是术后第二天早上的 6-MWD;次要结局包括疼痛评分、阿片类药物消耗、术后恶心和呕吐以及疲劳评分。
在计划的中期分析显示 64 例患者的利多卡因达到了预先计划的无效边界后,研究停止,其中 202±66m 分别为利多卡因与安慰剂相比,202±73m,平均差值(中期调整的 97.5%置信区间)为 0.93m(-52,54)(P=0.96);氯胺酮的作用也达到了无效边界,其中 193±77m 分别为氯胺酮与安慰剂相比,210±61m,平均差值(中期调整的 97.5%置信区间)为-11m(-65,44)(P=0.54)。未观察到两种干预效果之间的相互作用(P=0.96)。两种干预措施均未显著影响任何次要结局。
我们的结果不支持在开腹子宫切除术后第二天使用利多卡因或氯胺酮来改善 6-MWD。